Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Mocetinostat: Additional Phase II data

Additional data from an open-label, North American Phase II trial in 72 patients showed that thrice-weekly 70-100 mg oral mocetinostat led to an ORR of 17% in patients with DLBCL (n=41) and 10% in

Read the full 340 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE